Full Press Release Details
Biodexa Pharmaceuticals PLC
("Biodexa" or the "Company")
Exercise of Pre-Funded Warrants and
Biodexa Pharmaceuticals PLC (AIM: BDRX; Nasdaq: BDRX),
a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has today
issued to investors 11,001,255 new ordinary shares of 0.02 each in the Company ("New Ordinary Shares"), pursuant to
exercise notices in respect of 2,200,251 Pre-Funded Warrants received on 6 April 2023. All of these exercised Pre-Funded Warrants were
net exercised on a cashless basis. Further details are set out in the Company's circular dated 7 March 2023.
Admission and total voting rights
Application has been made to the London Stock Exchange
plc for the admission to trading on AIM of the New Ordinary Shares, which is expected to become effective and dealings commence at 8.00
a.m. on or around 17 April 2023 ("Admission"). The New Ordinary Shares will rank pari passu
with the existing ordinary shares.
The Company's enlarged issued share capital on Admission will
comprise 88,353,947 ordinary shares, each with voting rights. The Company does not hold any shares in treasury. From Admission, expected
to take place on 17 April 2023, this figure of 88,353,947 ordinary shares may be used by shareholders in the Company as the denominator
for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in,
the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Unless otherwise defined, capitalised terms used
in this announcement have the same meanings as ascribed to them in the Company's circular dated 7 March 2023.
contains inside information for the purposes of Article 7 of EU Regulation 596/2014, as it forms part of UK domestic law by virtue of
the European Union (Withdrawal) Act 2018, as amended.
For more information, please contact:
Biodexa Pharmaceuticals PLC
Stephen Stamp, CEO, CFO
Tel: +44 (0)29 2048 0180
Strand Hanson Limited (Nominated
James Dance / Matthew Chandler / Rob
Tel: +44 (0)20 7409 3494
IFC Advisory Limited (Financial
PR and UK Investor Relations)
Tim Metcalfe / Graham Herring
Tel: +44 (0)20 3934 6630
Edison Group (US Investor Relations)
Tel: +1 (860) 573 9637
Email: afactor@edisongroup.com
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (dual listed on AIM: BDRX; and NASDAQ:
BDRX) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company
combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products
that have the potential to powerfully impact the lives of patients.
The Company has developed three in-house technology platforms,
each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have
successfully entered human use in the clinic, providing important validation of the potential for each platform:
The platform nature of the technologies offers the potential
to develop multiple drug assets rather than being reliant on a limited number of programmes. Biodexa's technologies are supported
by 36 patent families including 120 granted patents and an additional 70 patent applications. Biodexa's headquarters and R&D
facility is in Cardiff, UK.
Forward-Looking Statements
Certain statements in this announcement
may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States.
Any forward-looking statements are based on currently available competitive, financial and economic data together with management's
views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks
and uncertainties. The Company wishes to caution you that there are some known and unknown factors that could cause actual results to
differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.
Reference should be made to those documents
that the Company shall file from time to time or announcements that may be made by the Company in accordance with the London Stock Exchange's
AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations
promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual
results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak
only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning the Company are
expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or
by relevant law in the United Kingdom or the United States, the Company does not undertake any obligation to publicly update or revise
any forward-looking statements because of new information, future events or otherwise arising.